Krystal Biotech, Inc. (KRYS) Earnings History
Annual and quarterly earnings data from 2016 to 2025
Loading earnings history...
KRYS EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
KRYS Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 92.6% | 41.5% | 52.6% |
| 2024 | 93.1% | 22.6% | 30.7% |
| 2023 | 93.9% | -216.4% | 21.6% |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export KRYS earnings history in CSV or JSON format
Free sign-in required to download data
Krystal Biotech, Inc. (KRYS) Earnings Overview
As of May 8, 2026, Krystal Biotech, Inc. (KRYS) reported trailing twelve-month net income of $225M, reflecting +128.0% year-over-year growth. The company earned $7.38 per diluted share over the past four quarters, with a net profit margin of 52.6%.
Looking at the long-term picture, KRYS's historical earnings data spans multiple years. The company achieved its highest annual net income of $205M in fiscal 2025, representing a new all-time high.
Krystal Biotech, Inc. maintains industry-leading profitability with a gross margin of 92.6%, operating margin of 41.5%, and net margin of 52.6%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including RCKT (-$223M net income), RARE (-$609M net income, -85.4% margin), FOLD (-$27M net income, -4.3% margin), KRYS has comparable earnings metrics. Compare KRYS vs RCKT →
KRYS Earnings vs Peers
Earnings metrics vs comparable public companies
KRYS Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $205M | +129.7% | $161M | $6.84 | 52.6% | 41.5% |
| 2024 | $89M | +715.6% | $66M | $3.00 | 30.7% | 22.6% |
| 2023 | $11M | +107.8% | -$110M | $0.39 | 21.6% | -216.4% |
| 2022 | -$140M | -101.2% | -$145M | $-5.49 | - | - |
| 2021 | -$70M | -116.3% | -$68M | $-3.13 | - | - |
| 2020 | -$32M | -68.5% | -$33M | $-1.71 | - | - |
| 2019 | -$19M | -75.3% | -$22M | $-1.20 | - | - |
| 2018 | -$11M | -37.5% | -$12M | $-0.97 | -1060.3% | -1160.3% |
| 2017 | -$8M | -588.7% | -$5M | $-1.48 | - | - |
| 2016 | -$1M | - | -$1M | $-0.27 | - | - |
See KRYS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KRYS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KRYS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKRYS — Frequently Asked Questions
Quick answers to the most common questions about buying KRYS stock.
Is KRYS growing earnings?
KRYS EPS is $7.38, with earnings growth accelerating to +128.0%. This exceeds the 5-year CAGR of N/A. TTM net income reached $225M.
What are KRYS's profit margins?
Krystal Biotech, Inc. net margin is +52.6%, with operating margin at +41.5%. Above-average margins indicate pricing power.
How consistent are KRYS's earnings?
KRYS earnings data spans 2016-2025. The accelerating earnings trend is +128.0% YoY. Historical data enables comparison across business cycles.